Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “United Kingdom”

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesRecruiting
NCT07351045Phase 3Updated Aug 14, 2026
Sponsor: Hoffmann-La Roche
Obesity or Overweight
United States, Argentina, Australia, Belgium, Brazil +15 more
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCTCompleted
NCT04173533Phase 3Updated Aug 14, 2026
Sponsor: University of Birmingham
Acute Myeloid Leukemia · Myelodysplasia
United Kingdom
Colchicine And Dialysis Patients; a Feasibility StudyRecruiting
NCT07762807NAUpdated Aug 13, 2026
Sponsor: King's College London
Haemodialysis Patients · Colchicine · Feasibility Study
United Kingdom
Surgical Procedure Efficiency Evaluation stuDyRecruiting
NCT07228091N/AUpdated Aug 13, 2026
Sponsor: Alcon Research
Cataract · Vitreous Hemorrhage · Retinal Detachment · Macular Pucker
United Kingdom
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionCompleted
NCT04569032Phase 2Updated Aug 13, 2026
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
United States, France, Italy, Spain, United Kingdom
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell LiposarcomaCompleted
NCT06703346Phase 2Updated Aug 13, 2026
Sponsor: USWM CT, LLC
Neoplasms
United States, Canada, France, Italy, Netherlands +2 more
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseCompleted
NCT02782663Phase 2Updated Aug 13, 2026
Sponsor: AbbVie
Crohn's Disease (CD)
United States, Belgium, Canada, Czechia, Denmark +13 more
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompleted
NCT03782207N/AUpdated Aug 13, 2026
Sponsor: Hoffmann-La Roche
Urothelial Carcinoma · Non-Small Cell Lung Cancer · Small Cell Lung Cancer · Hepatocellular Carcinoma
Argentina, Austria, Belgium, Brazil, Bulgaria +25 more
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44Recruiting
NCT07037862Phase 1, Phase 2Updated Aug 13, 2026
Sponsor: Entrada Therapeutics, Inc.
Duchenne Muscular Dystrophy (DMD)
Belgium, Italy, Spain, United Kingdom
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive Not Recruiting
NCT03332797Phase 1Updated Aug 13, 2026
Sponsor: Genentech, Inc.
Breast Cancer
United States, Australia, South Korea, Spain, United Kingdom
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyActive Not Recruiting
NCT06309966Phase 2, Phase 3Updated Aug 13, 2026
Sponsor: Biohaven Therapeutics Ltd.
Focal Epilepsy
United States, Australia, Denmark, Finland, Germany +11 more
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate CancerRecruiting
NCT07082920Phase 1Updated Aug 13, 2026
Sponsor: Janssen Research & Development, LLC
Prostatic Neoplasms
United States, United Kingdom
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaEnrolling By Invitation
NCT06609239Phase 2Updated Aug 13, 2026
Sponsor: Sanofi
Asthma
United States, Argentina, Brazil, Canada, Chile +9 more
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesRecruiting
NCT06980116Phase 1Updated Aug 13, 2026
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Relapsed or Refractory B-cell Malignancies · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) · Follicular Lymphoma (FL) · Marginal Zone Lymphoma (MZL)
Georgia, Greece, Moldova, Poland, Spain +2 more
Outpatient Treatment With Anti-Coronavirus ImmunoglobulinTerminated
NCT04910269Phase 3Updated Aug 13, 2026
Sponsor: University of Minnesota
COVID · SARS-CoV2 Infection · Covid19
United States, Argentina, Australia, Denmark, Greece +8 more
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)Enrolling By Invitation
NCT06191315Phase 3Updated Aug 13, 2026
Sponsor: Sanofi
Wheezing · Asthma
United States, Argentina, Brazil, Canada, Czechia +11 more
The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip ReplacementRecruiting
NCT06162195NAUpdated Aug 13, 2026
Sponsor: Embody Orthopaedic Limited
Osteoarthritis, Hip · Inflammatory Arthritis
United Kingdom
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)Completed
NCT06021054Phase 3Updated Aug 13, 2026
Sponsor: Viridian Therapeutics, Inc.
Thyroid Eye Disease
United States, Australia, France, Germany, Hungary +4 more
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45Recruiting
NCT07038824Phase 1, Phase 2Updated Aug 13, 2026
Sponsor: Entrada Therapeutics, Inc.
Duchenne Muscular Dystrophy (DMD)
Belgium, Italy, Netherlands, Spain, United Kingdom
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease PatientsActive Not Recruiting
NCT03814746Phase 3Updated Aug 13, 2026
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
United States, Belgium, Brazil, Canada, Colombia +16 more
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal DiseaseCompleted
NCT03020303Phase 3Updated Aug 13, 2026
Sponsor: Hamilton Health Sciences Corporation
Endstage Renal Disease
Australia, Brazil, Canada, China, Ecuador +7 more
PulseSelect™ PFA Global RegistryRecruiting
NCT06393920N/AUpdated Aug 13, 2026
Sponsor: Medtronic Cardiac Ablation Solutions
Atrial Fibrillation
Belgium, Canada, China, Croatia, France +10 more
Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsRecruiting
NCT05985655Phase 1, Phase 2Updated Aug 13, 2026
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC) · Pancreatic Adenocarcinoma · Non-small Cell Lung Cancer (NSCLC) · Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
United States, Belgium, United Kingdom
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) PatientsCompleted
NCT01784068Phase 2Updated Aug 13, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
United States, Argentina, Austria, Belgium, Bulgaria +14 more
Investigating the Impact of Early Time-Restricted Eating on Health Outcomes and Quality of Life in Adults With Mild Controlled Asthma Compared to Healthy AdultsRecruiting
NCT07345572NAUpdated Aug 13, 2026
Sponsor: De Montfort University
Asthma Management · Time Restricted Eating
United Kingdom

Previous page Next page